Microbot Medical (MBOT) announced that it has been granted a critical patent in China by the China National Intellectual Property Administration, CNIPA, a key step in the Company’s global IP expansion strategy. The patent, which covers the robotic manipulation of a surgical tool handle, further validates the Company’s technological innovation and expands its intellectual property portfolio. This milestone demonstrates Microbot’s continued commitment to protect its proprietary technology as it builds a broader global commercialization strategy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBOT:
- Microbot Medical Approves Key Proposals at Annual Meeting
- Microbot Medical’s Strategic Growth and LIBERTY System’s Market Readiness Drive Buy Rating
- Microbot Medical Expands Team Ahead of LIBERTY Launch
- Microbot Medical expands commercial team ahead of LIBERTY system launch
- Microbot Medical Selected for Russell Microcap Index
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue